Sanofi is making a big bet on blood disorders with the $11.6bn acquisition of Bioverativ Inc. The acquisition, announced Jan. 22, will position Sanofi as a leader in hemophilia, but the competition in the category is fierce and the prospect of gene therapy sits just on the horizon, raising questions about the steep premium Sanofi has paid.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?